6-ketoprostaglandin-f1-alpha and Vomiting

6-ketoprostaglandin-f1-alpha has been researched along with Vomiting* in 3 studies

Other Studies

3 other study(ies) available for 6-ketoprostaglandin-f1-alpha and Vomiting

ArticleYear
Plasma prostaglandin levels in patients with gynecologic malignancies and its fluctuations during chemotherapeutically-induced gastrointestinal toxicity.
    Japanese journal of clinical oncology, 1987, Volume: 17, Issue:3

    Peripheral plasma prostaglandins (PGs) were assayed in 10 cases of gynecologic malignancies. In addition, fluctuations of PG levels during chemotherapeutically-induced gastrointestinal toxicity as well as those caused by a bolus infusion of steroid hormone were investigated. As a result, the level of PGE2 in most cases of gynecologic malignancies was seen above or around the upper limit of that in healthy women. During chemotherapy, the levels of PGF2 alpha and thromboxane B2 (TxB2) increased significantly compared to baseline levels (P less than 0.05). A bolus infusion of steroid hormone did not bring about any noticeable change in any of the levels of PGF2 alpha, TxB2, PGE2 or 6K. It may be inferred from these findings that PGs are synthesized in tumor tissue itself and released into plasma. Also, the finding that the levels of peripheral plasma PGs increased during chemotherapy suggested that such an increase in PG release could be one of the factors causing gastrointestinal toxicity. Based on the fact that there were no changes in levels of peripheral plasma PGs due to the administration of steroid hormone, however, we failed to support the proposal that steroid hormone suppresses the release of PG.

    Topics: 6-Ketoprostaglandin F1 alpha; Antineoplastic Combined Chemotherapy Protocols; Dinoprost; Dinoprostone; Female; Humans; Hydrocortisone; Nausea; Ovarian Neoplasms; Prostaglandins; Prostaglandins E; Prostaglandins F; Radioimmunoassay; Thromboxane B2; Uterine Neoplasms; Vomiting

1987
Effect of ionizing radiation on prostaglandins and gastric secretion in rhesus monkeys.
    Radiation research, 1987, Volume: 110, Issue:2

    Early radiation toxicity is characterized by nausea and vomiting. We have previously shown that gastric emptying, gastric motility, and gastric secretion were suppressed after total body exposure to irradiation. In the present studies, we evaluated the relation between vomiting and gastric function in nine rhesus monkeys and explored the possible role of prostaglandins (PG) in these phenomena. The concentration of PG in plasma and gastric juice was determined using a standard radioimmunoassay and gastric acid output was measured concurrently using a marker dilution technique. The animals were studied in the basal state and after total body exposure to 800 cGy 60Co delivered at a rate of 500 cGy/min. Acid output was abolished from 40 min to 2 h after irradiation but had returned to preirradiation levels 2 days later. Plasma PGE2 and PGI2 (as measured by 6-keto-PGF1 alpha determination) were not significantly modified by irradiation. In contrast, irradiation produced an immediate significant increase (P less than 0.05) in gastric juice concentration of PGE2 (318 +/- 80 to 523 +/- 94 pg/ml; mean +/- SE) and PGI2 (230 +/- 36 to 346 +/- 57 pg/ml); both had returned to basal levels 2 days later. Thus, an increase in gastric juice concentration of both PGE2 and PGI2 is associated with the radiation induced suppression of acid output.

    Topics: 6-Ketoprostaglandin F1 alpha; Acute Disease; Animals; Dinoprostone; Gamma Rays; Gastric Acid; Gastric Emptying; Gastric Mucosa; Gastrointestinal Motility; Macaca mulatta; Prostaglandins E; Radiation Injuries, Experimental; Vomiting; Whole-Body Irradiation

1987
Plasma 6-keto-prostaglandin F1 alpha in disorders involving hypokalemia.
    Prostaglandins, leukotrienes, and medicine, 1982, Volume: 9, Issue:5

    We measured plasma levels of 6-keto-prostaglandin F1 alpha by radioimmunoassay in patients with hypokalemia due to various disorders. Plasma 6-keto-PGF1 alpha in patients with disorders involving hypokalemia was not different from that of normal controls. Treatment with inhibitors of prostaglandin synthesis for 5-7 days in three patients with Bartter's syndrome decreased 6-keto-PGF1 alpha plasma levels by about 25%. It is suggested that, plasma 6-keto-PGF1 alpha may, on occasions, be a poor index of circulating prostacyclin.

    Topics: 6-Ketoprostaglandin F1 alpha; Bartter Syndrome; Cathartics; Female; Humans; Hypokalemia; Substance-Related Disorders; Vomiting

1982
chemdatabank.com